Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study.
- DOI
- 10.1093/ibd/izag185
- Published
- 2026 Sep 23
- Container
- Inflammatory bowel diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ibd/izag185,
title = {Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study.},
author = {He D and Sha S and Liu X and Yin P and Qu X and Wang X and Wang N and Feng X and Zhang Z and Zhang W and Shi Y and Chen M},
year = {2026},
journal = {Inflammatory bowel diseases},
doi = {10.1093/ibd/izag185},
url = {https://doi.org/10.1093/ibd/izag185}
}RIS
TY - JOUR TI - Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study. AU - He D AU - Sha S AU - Liu X AU - Yin P AU - Qu X AU - Wang X AU - Wang N AU - Feng X AU - Zhang Z AU - Zhang W AU - Shi Y AU - Chen M PY - 2026 JO - Inflammatory bowel diseases DO - 10.1093/ibd/izag185 UR - https://doi.org/10.1093/ibd/izag185 ER -
APA
D, H., S, S., X, L., P, Y., X, Q., X, W., N, W., X, F., Z, Z., W, Z., Y, S., & M, C. (2026). Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study.. Inflammatory bowel diseases. https://doi.org/10.1093/ibd/izag185
Source records
- pubmed · retrieved 2026-09-25T04:56:27.280Z